Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study;Eficacia de rituximab comparado con ciclofosfamida en pacientes con manifestaciones graves de lupus eritematoso generalizado. Estudio aleatorizado y multicéntrico

Reumatologia Clinica

Volumn 6, Issue 5, 2010, Pages 250-255

  Andrade Ortega, Lilia ^a   Irazoque Palazuelos, Fedra ^a   López Villanueva, Ricardo ^b   Barragán Navarro, Yaneth ^a   Bourget Pietrasanta, Fernando ^c   Díaz Ceballos, Maria de los Ángeles ^d   Hernández Paz, Roberto ^e   Urenda Quezada, Adelfia ^f   Rivas Ruiz, Rodolfo ^g  

^a Centro Médico Nacional 20 de Noviembre   (Mexico)

^b Hospital Regional Mérida del ISSSTE   (Mexico)

^c CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^d Hospital General Dario Fernandez Fierro   (Mexico)

^e Hospital Regional del ISSSTE   (Mexico)

^f Hospital Regional del ISSSTE   (Mexico)

^g HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

B cells; C lulas B; Ciclofosfamida; Cyclophosphamide; Lupus grave; Rituximab; Severe lupus

Indexed keywords

ANTINUCLEAR ANTIBODY; CYCLOPHOSPHAMIDE; RITUXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 77956611409     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2009.11.004     Document Type: Article

References (29)

1. Driver C., Ishimori M., Weisman M. The B cell in systemic lupus erythematosus: a rational target for more effective therapy. Ann Rheum Dis 2008, 67:1374-1381.
2. Tikly M. Lupus in the developing world - is it any different?. Best Pract Res Clin Rheumatol 2008, 22:643-655.
3. Sfikakis P., Boletis J., Tsokos C. Rituximab anti-B cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005, 17:550-557.
4. Eisenberg R. Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20). Endocr Metab Immune Disord Drug Targets 2006, 6:345-350.
5. Sanz I. New therapies for systemic lupus erythematosus: Cellular targets. Rheum Dis Clin North Am 2006, 32:201-215.
6. Dörner T., Burmester G. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 2008, 20:263-268.
7. Taylor R., Lindorfer M. Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007, 3:86-95.
8. Petschner F., Walker U.A., Schmidtt-Graff A., Uhl M., Peter H.H. «Catastrophic systemic lupus erythematosus» with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rituximab. Dtsch Med Wochenschr 2001, 126:998-1001.
9. Sailler L. Rituximab off label use for difficult-to-treat auto-immune diseases: Reappraisal of benefits and risks. Clin Rev Allergy Immunol 2008, 34:103-110.
10. Ramos-Casals M., Soto M.J., Cuadrado M.J., Khamashta M.A. Rituximab in systemic lupus erythematosus. A systematic review of off-label use in 188 cases. Lupus 2009, 18:767-776.
11. Guzman J., Cardiel M.H., Arce-Salinas A., Sanchez-Guerrero J., Alarcón-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992, 19:1551-1558.
12. Leandro M., Edwards J., Cambridge G., Ehrenstein M., Isenberg D. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002, 46:2673-2677.
13. Leandro M., Cambridge G., Edwards J., Ehrenstein M., Isenberg D. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005, 44:1542-1545.
14. Ng K.P., Cambridge G., Leandro M., Edwards J., Ehrenstein M., Isenberg D. B cell depletion therapy in systemic lupus erythematosus: long term follow -up and predictors of response. Ann Rheum Dis 2007, 66:1259-1262.
15. Lu T., NG K., Cambridge G., Leandro M., Edwards J., Ehrenstein M., et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college London hospital: The first fifty patients. Arthritis Rheum 2009, 61:482-487.
16. Looney R., Anolik J., Campbell D., Felgar R., Young F., Arend L., et al. B cell depletion as a novel treatment for systemic lupus erythematosus. A phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004, 50:2580-2589.
17. Anolik J., Barnard J., Cappione A., Pugh-Bernard A., Felgar R., Looney R., et al. Rituximab improves peripheral B cells abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004, 50:3580-3590.
18. Cambridge G., Leandro M., Teodorescu M., Manson J., Rahman A., Isenberg D., et al. B cell depletion therapy in systemic lupus erythematosus. Effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006, 54:3612-3622.
19. Albert D., Dunham J., Khan S., Stansberry J., Kolasinski S., Tsai D., et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis 2008, 67:1724-1731.
20. Sfikakis P., Boletis J., Lionaki S., Vigklis V., Fragiadaki G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand. Arthritis Rheum 2005, 52:501-513.
21. Vigna-Perez M., Hernández-Castro B., Paredes-Saharopulos O., Portales-Pérez D., Baranda L., Abud-Mendoza C., et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006, 8:R83. Epub 2006 May 5.
22. Camous L., Melander C., Vallet M., Squalli T., Knebelmann B., Noël L.H., et al. Complete Remission of Lupus Nephritis With Rituximab and Steroids for Induction and Rituximab Alone for Maintenance Therapy. Am J Kidney Dis 2008, 52:346-352.
23. Li E.K., Tam L.S., Zhu T.Y., Li M., Kwok C.L., Li T.K., et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?. Rheumatology 2009, 48:892-898.
24. Tokunaga M., Saito K., Kawabata D., Imura Y., Fujii T., Nakayamada S., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007, 66:470-475.
25. Tanaka Y., Tamamoto K., Takeuchi T., Nishimoto N., Miyasaka N., Sumida T., et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007, 17:191-197.
26. Jónsdóttir T., Gunnarsson I., Risselada A., Henriksson E.W., Klareskog L., van Vollenhoven R.F. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008, 67:330-334.
27. A study to evaluate the efficacy and safety of rituximab in patients with severe systemic lupus erythematosus (EXPLORER). Disponible en: http://clinicaltrials.gov/ct/show/NCT00137969.
28. Study to evaluate the efficacy and safety of rituximab in subjects with ISN/RPS class III or IV lupus nephritis (LUNAR). Disponible en: http://clinicaltrials.gov/ct/show/NCT00282347.
29. Tahir H., Rohrer J., Bhatia A., Wegener W., Isenberg D. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 2005, 44:561-562.